Fc effector function in bNAbs
Fc effector function in bNAbs
批准号:
9208096
负责人:
JEFFREY Victor RAVETCH
金额:
$50.85万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Amino AcidsAnimal ModelAnimalsAntibodiesAntigen TargetingBacterial ToxinsBindingBiochemicalBiological AssayCCR5 geneCD34 geneCellsCollaborationsComplexDataDevelopmentEngineeringExhibitsFc domainFetal LiverGenerationsHIVHIV AntibodiesHIV InfectionsHepatocyteHumanImmunityImmunizationImmunoglobulin GIn VitroInfluenzaLinkLuciferasesMediatingModelingModificationMusPathway interactionsPolysaccharidesPropertyRoleRosaServicesSpecificityStandardizationStructureSystemTestingTransgenic OrganismsVaccinationValidationVariantViralVirusadeno-associated viral vectorbasedefined contributionglobal healthhumanized mouseimmunogenicityin vitro testingin vivoin vivo Modelmouse modelneutralizing antibodynovelpreventprotein expressionreconstitution
中文摘要
最近的研究强调了Fc-FCR相互作用对实现体内保护的重要性
通过ADCC和ADCC等机制中和HIV和其他病毒或细菌毒素的抗体
ADCVL.我们已经定义了Ig G Fc与FcγRs结合所需的氨基酸和多糖
基于新品系的FcγR人源化小鼠建立动物模型以确定氨基酸的影响
人免疫球蛋白的酸和多糖修饰对其体内功能的影响。尽管越来越多的人对
Fc介导的效应器功能对抗体介导的病毒体内效力的重要性
对于bNAbs对HIV的中和,还没有进行系统的研究来确定最佳的Fc
将导致这些活动的结构。我们将表征Fc结构和效应器的贡献
对Nussenzweig分离的bNAbs的活性的影响,并产生优化的修饰bNAbs
FC效应器函数。这些重新设计的bNAbs将在体外进行中和、ADCC和
ADCVBI和与Nussenzweig合作,在一种基于TZM-bl的新的体内中和试验中
在携带人FcγR的小鼠中进行检测。与比约克曼合作,我们将获得
这些修饰的抗体Fc单独或与特定的FcγR复合,这些数据将指导产生
额外的变种,进一步增强FC-FCγR功能。这些研究将导致产生
新颖的bNAbs,针对中和和效应器功能进行了优化,并提供了开发框架
免疫策略将导致bNAbs具有最佳的效应器特性。
英文摘要
Recent studies have highlighted the significance of Fc-FcR interactions to achieve in vivo protection for
neutralizing antibodies to HIV and other viruses or bacterial toxins through mechanisms including ADCC and
ADCVl. We have defined both the amino acid and glycan requirements for IgG Fc binding to FcγRs and
developed animal models based on novel strains of FcγR humanized mice to determine the impact of amino
acid and glycan modifications of human IgGs on their in vivo function. Despite the growing appreciation for
the importance of Fc mediated effector functions to the in vivo potency of antibody mediated viral
neutralization for bNAbs to HIV, no systematic studies have been performed to determine the optimal Fc
structure that will result in these activities. We will characterize the contributions of Fc structure and effector
functions to the activities of the bNAbs isolated by Nussenzweig and generate modified bNAbs optimized for
Fc effector functions. These re-engineered bNAbs will be tested in vitro for neutralization, ADCC and
ADCVBI and, in collaboration with Nussenzweig, in a novel in vivo neutralization assay, based on the TZM-bl
assay in mice that carry human FcγR. In collaboration with Bjorkman we will obtain structural information for
these modified antibody Fc's, alone and in complex to specific FcγRs, These data will direct the generation
of additional variants to further enhance Fc-FcγR function. These studies will result in the generation of
novel, bNAbs optimized for both neutralization and effector function and provide the framework to develop
immunization strategies that will result in bNAbs with optimal effector properties.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project-003
-
批准号:10170029
-
项目类别:
-
资助金额:$62.61万
-
财政年份:2020
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:10265794
-
项目类别:
-
资助金额:$150.0万
-
财政年份:2020
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Project-002
-
批准号:10169069
-
项目类别:
-
资助金额:$87.39万
-
财政年份:2020
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Molecular mechanisms of antibody-mediated immunotherapies
-
批准号:10368931
-
项目类别:
-
资助金额:$99.67万
-
财政年份:2016
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Molecular mechanisms of antibody-mediated immunotherapies
-
批准号:10684073
-
项目类别:
-
资助金额:$44.75万
-
财政年份:2016
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Molecular mechanisms of antibody-mediated immunotherapies
-
批准号:8940844
-
项目类别:
-
资助金额:$101.7万
-
财政年份:2016
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Molecular mechanisms of antibody-mediated immunotherapies
-
批准号:10518790
-
项目类别:
-
资助金额:$101.7万
-
财政年份:2016
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Molecular mechanisms of antibody-mediated immunotherapies
-
批准号:9888968
-
项目类别:
-
资助金额:$101.7万
-
财政年份:2016
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain
-
批准号:8933343
-
项目类别:
-
资助金额:$31.55万
-
财政年份:2015
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Administrative Core
-
批准号:10595523
-
项目类别:
-
资助金额:$21.12万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:10595522
-
项目类别:
-
资助金额:$208.74万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:9884701
-
项目类别:
-
资助金额:$208.79万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:10386775
-
项目类别:
-
资助金额:$208.75万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Administrative Core
-
批准号:10386776
-
项目类别:
-
资助金额:$41.75万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:8827238
-
项目类别:
-
资助金额:$243.34万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:8707655
-
项目类别:
-
资助金额:$243.54万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Fc domain effector activity in dengue disease
-
批准号:10595526
-
项目类别:
-
资助金额:$58.61万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Fc domain effector activity in dengue disease
-
批准号:10386779
-
项目类别:
-
资助金额:$41.75万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:9035353
-
项目类别:
-
资助金额:$243.34万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
FcR Deficient Mice Susceptibility to Pathogens
-
批准号:8261151
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2011
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
海外基金